Quick Answer
Arcturus Therapeutics Holdings Inc. reported Long-Term Debt of $40.63 million for fiscal year 2021.
Arcturus Therapeutics Holdings Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2021 | $40.63M | +193.5% |
| 2020 | $13.85M | -7.7% |
| 2019 | $14.99M | +51.3% |
| 2018 | $9.91M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $15.00M | — | -25.0% |
| September 30, 2023 | $20.00M | -37.6% | -37.6% |
| September 30, 2022 | $32.04M | -24.3% | -10.4% |
| June 30, 2022 | $35.76M | -36.5% | -8.9% |
| March 31, 2022 | $39.23M | -32.5% | -3.4% |
| December 31, 2021 | $40.63M | +193.5% | -4.0% |
| September 30, 2021 | $42.34M | +180.9% | -24.8% |
| June 30, 2021 | $56.31M | +273.9% | -3.2% |
- Arcturus Therapeutics Holdings Inc. showed an increase of +193.5% in Long-Term Debt compared to the prior fiscal year.
- Over the 2018–2021 period, Arcturus Therapeutics Holdings Inc.’s long-term debt has grown by 310.0% (from $9.91 million to $40.63 million).
- The most recent figure is from Arcturus Therapeutics Holdings Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 29, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: